Neurokinin-1 receptor antagonist

Phase 3Small molecule

Neurokinin-1 receptor antagonist is one of 107 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Carcinoma, Non-Small-Cell LungRecruiting

Nausea and VomitingPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Neurokinin-1 receptor antagonist

Merck & Co.

Phase 3

2 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Remeron

OOrganon and Co

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780085

Clinical

Trials by Indication[1]

Nausea and vomiting1 trial

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 3·NCT04503668·62 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780085·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Neurokinin-1 receptor antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neurokinin-1 receptor antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neurokinin-1 receptor antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Neurokinin-1 receptor antagonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Nausea and vomiting1 trial

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News